ArticleMedicine2026
Clinical effectiveness of high-flow nasal cannula oxygen therapy in post-cardiac surgery hypoxemia: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This retrospective cohort study aims to evaluate the clinical effectiveness of high-flow nasal cannula oxygen therapy (HFNCO) in managing hypoxemia following cardiac surgery. Baseline characteristics were comparable between groups (P > .05). At 6 hours post-extubation, the HFNCO group demonstrated significantly lower respiratory rate (20.16 vs 22.19 breaths/min, P = .001), higher pH (7.42 vs 7.46, P = .001), reduced PaCO2 (36.66 vs 40.35 mm Hg, P = .001), and improved P/F ratio (298.05 vs 237.45, P < .001). High-flow nasal cannula oxygen therapy reduced intensive care unit length of stay (ICU LOS; 3.21 vs 7.32 days, P < .001), total hospital LOS (23.69 vs 33.07 days, P = .002), reintubation rate (2% vs 14%, P = .002), and ICU delirium incidence (5% vs 17%, P = .007). No mortality difference was observed (P > .05). High-flow nasal cannula oxygen therapy was associated with improved oxygenation, enhanced CO2 clearance, and a reduction in clinical complications in post-cardiac surgery hypoxemia. It may be a valuable alternative to conventional oxygen therapy, warranting further validation in multicenter trials. A total of 203 patients with hypoxemia (PaO2 < 60 mm Hg, SpO2 < 90%, or P/F ≤ 300 mm Hg) after cardiac surgery (January 2021-January 2024) were included. Participants were divided into conventional oxygen therapy (n = 101) and HFNCO (n = 102) groups. Primary outcomes included respiratory rate, blood gas parameters (pH, PaCO2, PaO2/FiO2), and secondary outcomes encompassed ICU/LOS, reintubation rate, and ICU-acquired delirium. Statistical analyses were performed using SPSS 26.0.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.